Tag:
ribavirin
Latest Headlines
Latest Headlines
Boehringer advances hep C contender into pivotal trial
Boehringer Ingelheim has begun enrolling patients in a pivotal late-stage hepatitis C study. The therapy combines faldaprevir (BI 201335), a protease inhibitor administered once daily, and BI 207127, a non-nucleoside polymerase inhibitor taken twice daily, plus ribavirin.
Abbott's interferon-free hep C combo wows in PhIIb test
Abbott Laboratories made a late entry into the red-hot race to develop an interferon-free approach to hepatitis C. But after playing catch-up with the likes of Gilead, it's now aiming for the inside track.
Abbott wows the crowd with promising Phase II hep C data
You can count Abbott as a key player in the hot hepatitis C drug development race.
